NCT06637215 Clinical Research on the Treatment Model of Ambulatory Surgery for Colorectal Cancer
| NCT ID | NCT06637215 |
| Status | Recruiting |
| Phase | — |
| Sponsor | First Hospital of China Medical University |
| Condition | Colorectal Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 352 participants |
| Start Date | 2023-11-01 |
| Primary Completion | 2026-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 352 participants in total. It began in 2023-11-01 with a primary completion date of 2026-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To investigate the postoperative complication incidence and long-term efficacy between ambulatory surgery for colorectal cancer and traditional laparoscopic colorectal surgery in patients with colorectal tumor who are generally in good health and have sufficient organ functions。
Eligibility Criteria
Inclusion Criteria: 1. Patients voluntarily joined this study and signed an informed consent form； 2. Age: 18-75 years old； 3. The patient should have a good general condition and no serious internal medicine comorbidities (ASA classification of the American Anesthesiology Association is Grade I\~III)； 4. Complete colonoscopy and colonoscopy biopsy, and the pathology is confirmed to be adenocarcinoma/high-level intraepithelial neoplasia； 5. Enhanced CT or MRI examination before surgery, indicating that the tumor diameter is ≤5.0 cm； 6. Preoperative staging: cT1-3NanyM0; 7. Strictly follow the colorectal day surgery plan, and micro-laparoscopic radical colorectal cancer treatment can be adopted； 8. There are no contraindications for abdominal wall nerve block anesthesia or non-opiate analgesic drugs; 9. Does not require conventional anticoagulant therapy or antiplatelet therapy； 10. Relatives or co-residents should be able to provide 24 hours of full escort within at least 72 hours after the operation, the place of residence is not more than a 30-minute drive from the hospital, and they can understand and follow the phased treatment plan of diet, analgesic drugs, etc. after the operation. Exclusion Criteria: 1. Elderly patients with multiple basic diseases； 2. Moderate to severe anemia； 3. Severe hypoproteinemia； 4. Diabetes that is not well controlled； 5. Contraindications to laparoscopic surgery； 6. Cases of emergency surgery due to acute intestinal obstruction, perforation or bleeding； 7. Patients with distant metastases； 8. Patients who are unwilling to sign informed consent or follow-up according to the research plan； 9. People with a history of psychotropic drug abuse and unable to quit or have mental disorders； 10. Patients who live alone or in psychosocial isolation, patients who cannot understand the postoperative nursing process； 11. After the operation, the place of residence is far away from the treated hospital or patients with insufficient medical resources and inconvenient transportation； 12. According to the judgment of the researcher, there are concomitant diseases that seriously endanger the safety of the patient or affect the completion of the patient\'s research.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06637215 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Colorectal Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06637215 currently recruiting?
Yes, NCT06637215 is actively recruiting participants. Contact the research team at cmu_likai@163.com for enrollment information.
Where is the NCT06637215 trial being conducted?
This trial is being conducted at Shenyang, China.
Who is sponsoring the NCT06637215 clinical trial?
NCT06637215 is sponsored by First Hospital of China Medical University. The trial plans to enroll 352 participants.